IOBT Historical Balance Sheet
| IOBT Stock | USD 0.89 0.04 4.71% |
Trend analysis of IO Biotech balance sheet accounts such as Other Current Liabilities of 5.6 M or Total Current Liabilities of 11.1 M provides information on IO Biotech's total assets, liabilities, and equity, which is the actual value of IO Biotech to its prevalent stockholders. By breaking down trends over time using IO Biotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining IO Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether IO Biotech is a good buy for the upcoming year.
IO Biotech Inventory |
|
IOBT |
About IOBT Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of IO Biotech at a specified time, usually calculated after every quarter, six months, or one year. IO Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of IO Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which IOBT currently owns. An asset can also be divided into two categories, current and non-current.
IO Biotech Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of IO Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in IO Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Accounts Payable
An accounting item on the balance sheet that represents IO Biotech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of IO Biotech are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most accounts from IO Biotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into IO Biotech current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IO Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy IOBT Stock please use our How to Invest in IO Biotech guide.At this time, IO Biotech's Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 374.9 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 11.1 M in 2024.
| 2023 | 2024 (projected) | Short and Long Term Debt Total | 2.5M | 3.7M | Total Assets | 150.7M | 118.8M |
IO Biotech balance sheet Correlations
Click cells to compare fundamentals
IO Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.